☆ 4.7 Editorial Material

KRASG12C inhibition in colorectal cancer Comment

LANCET ONCOLOGY (2022)

Journal

LANCET ONCOLOGY

Volume 23, Issue 1, Pages 10-11

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/S1470-2045(21)00652-5

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad, S. Liu, I. I. Rybkin, K. C. Arbour, J. Dilly, V. W. Zhu, M. L. Johnson, R. S. Heist, T. Patil, G. J. Riely, J. O. Jacobson, X. Yang, N. S. Persky, D. E. Root, K. E. Lowder, H. Feng, S. S. Zhang, K. M. Haigis, Y. P. Hung, L. M. Sholl, B. M. Wolpin, J. Wiese, J. Christiansen, J. Lee, A. B. Schrock, L. P. Lim, K. Garg, M. Li, L. D. Engstrom, L. Waters, J. D. Lawson, P. Olson, P. Lito, S. -H. I. Ou, J. G. Christensen, P. A. Janne, A. J. Aguirre

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Hajrah Khawaja, Rebecca Briggs, Cheryl H. Latimer, Mustasin Rassel, Dary Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S. McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas U. Lindner, Jochen H. M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck

Summary: Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant colorectal cancer. In this study, researchers found that the combination of AZ'1569 and a Bcl-xL inhibitor led to a dramatic and universal apoptosis, suggesting a potential therapeutic strategy for patients with KRAS G12C-mutant colorectal cancer.

MOLECULAR CANCER THERAPEUTICS (2023)

Add to Collection

Editorial Material Oncology

Precision oncology for KRASG12C-mutant colorectal cancer

Federica Di Nicolantonio, Alberto Bardelli

Summary: Allele-specific inhibitors of KRAS(G12C) have been approved for non-small-cell lung cancer. This article discusses recent results from the phase I/II KRYSTAL-1 trial of adagrasib alone and in combination with cetuximab in patients with KRAS(G12C)-mutant metastatic colorectal cancer. The combination treatment showed promising efficacy and, if confirmed in later-phase trials, simultaneous inhibition of EGFR and KRAS(G12C) will introduce a new paradigm in precision oncology.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

Targeting KRASG12C in colorectal cancer: the beginning of a new era

D. Ciardiello, B. A. Maiorano, E. Martinelli

Summary: RAS mutation is a significant oncogenic driver in human cancers, traditionally considered undruggable. The recent discovery of selective and potent KRASG12C inhibitors brings hope. However, their clinical activity in metastatic colorectal cancer with KRASG12C mutation is lower than expected, suggesting intrinsic resistance. Novel combinatory strategies to disrupt RAS signaling pathways are under investigation. This review discusses the current knowledge and novel routes of KRASG12C inhibition in metastatic colorectal cancer.

ESMO OPEN (2023)

Add to Collection

Review Biotechnology & Applied Microbiology

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

[Anonymous]

Summary: Identifying mutations in the KRAS gene is crucial for the treatment of colorectal cancer. The introduction of KRAS(G12C) inhibitors has shown safety and efficacy in preclinical studies and early phase trials, although not all tumor types with KRAS(G12C) mutations are responsive to monotherapy. Colorectal cancer patients have shown less benefit, possibly due to treatment-induced resistance through increased EGFR signaling. Combination therapy trials with EGFR inhibitors are currently underway.

ONCOTARGETS AND THERAPY (2022)

Add to Collection

Article Oncology

Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer

Jason T. Henry, Oluwadara Coker, Saikat Chowdhury, John Paul Shen, Van K. Morris, Arvind Dasari, Kanwal Raghav, Maliha Nusrat, Bryan Kee, Christine Parseghian, Shubham Pant, Nikeshan Jeyakumar, Limin Zhu, Yujiro Nishioka, David Fogelman, Robert A. Wolff, David Hong, Michael J. Overman, JeanNicolas Vauthey, Scott Kopetz, Benny Johnson

Summary: KRAS p.G12C mutations occur in 3% of metastatic colorectal cancers and have poor PFS and OS compared to KRAS nonG12C. These patients show innate resistance to chemotherapy and can serve as a historical comparator for future clinical trials.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Article Oncology

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition

Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, Eric B. Haura

Summary: The study reveals cell type-specific adaptive responses to KRASi, with epithelial cells compensating ERBB2/3 signaling and mesenchymal cells showing activation of FGFR or AXL signaling. These findings suggest the importance of considering cell type-specific markers and targets for patient enrichment strategies with KRASi.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Medicine, Research & Experimental

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

Pierre-Antoine Laurent, Marina Milic, Clement Quevrin, Lydia Meziani, Winchygn Liu, Daphne Morel, Nicolas Signolle, Celine Clemenson, Antonin Levy, Michele Mondini, Eric Deutsch

Summary: This study investigated the effects of a new KRAS(G12C) inhibitor, MRTX1257, on radio-sensitization of tumors. The results showed that MRTX1257 significantly enhanced the radio-sensitivity of CT26 KRAS(G12C+/+) cells, and similar effects were observed in a mouse model of tumors. Furthermore, the treatment also changed the tumor microenvironment towards a pro-inflammatory and anti-tumor phenotype.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Oncology

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

Daniel J. Sisler, Trista K. Hinz, Anh T. Le, Emily K. Kleczko, Raphael A. Nemenoff, Lynn E. Heasley

Summary: This study generated three novel mouse lung cancer cell lines with KRAS(G12C) mutation as models for further preclinical improvement of KRAS(G12C) inhibitors. The three cell lines exhibited similar in vitro sensitivities to the inhibitors, but showed distinct in vivo responses. These new models are valuable for identifying improved therapeutic strategies with KRAS(G12C) inhibitors.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Immunology

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Carmine Fedele, Shuai Li, Kai Wen Teng, Connor J. R. Foster, David Peng, Hao Ran, Paolo Mita, Mitchell J. Geer, Takamitsu Hattori, Akiko Koide, Yubao Wang, Kwan Ho Tang, Joshua Leinwand, Wei Wang, Brian Diskin, Jiehui Deng, Ting Chen, Igor Dolgalev, Ugur Ozerdem, George Miller, Shohei Koide, Kwok-Kin Wong, Benjamin G. Neel

Summary: The combination of SHP2 inhibitor and KRAS (G12C) inhibitor shows significant survival benefits in PDAC and NSCLC, inducing favorable changes in the tumor microenvironment by reducing myeloid suppressor cells, increasing CD8(+) T cells, and enhancing sensitivity to PD-1 blockade.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, Christopher Moore, Sareena Rana, Miriam Llorian Sopena, Philip East, Rachel Ambler, Panayiotis Anastasiou, Pablo Romero-Clavijo, Karishma Valand, Megan Cole, Miriam Molina-Arcas, Julian Downward

Summary: Recently developed KRAS(G12C) inhibitory drugs benefit lung cancer patients with KRAS(G12C) mutations, but drug resistance is common. These drugs indirectly affect antitumor immunity by reversing immunosuppression caused by oncogenic KRAS. However, the combination of KRAS(G12C) inhibitors with immune checkpoint blockade only provides synergistic benefit in highly immunogenic tumor models.

SCIENCE ADVANCES (2022)

Add to Collection

Article Oncology

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis

Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell'Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, Giovanni Dima, Giovanni Trovato, Silvia Riondino, Mario Roselli, Ferdinandos Skoulidis, Hendrik-Tobias Arkenau, Chiara Cremolini

Summary: This retrospective study compared the effectiveness of irinotecan and oxaliplatin in the first-line treatment of KRASG12C-mutated colorectal cancer. The results demonstrated that irinotecan provided better survival outcomes, indicating that it should be preferred over oxaliplatin. These findings are important for investigating chemotherapy plus targeted agent combinations.

CANCERS (2023)

Add to Collection

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne, Gregory J. Riely, Shirish M. Gadgeel, Rebecca S. Heist, Sai-Hong I. Ou, Jose M. Pacheco, Melissa L. Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo V. Negrao, Nathan A. Pennell, Jun Zhang, Kenna Anderes, Hirak Der-Torossian, Thian Kheoh, Karen Velastegui, Xiaohong Yan, James G. Christensen, Richard C. Chao, Alexander I. Spira

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cell Biology

DHOK Exerts Anti-Cancer Effect Through Autophagy Inhibition in Colorectal Cancer

Yuhan Shu, Xin Sun, Guiqin Ye, Mengting Xu, Zhipan Wu, Caixia Wu, Shouxin Li, Jingkui Tian, Haote Han, Jianbin Zhang

Summary: DHOK, a novel diterpene from the roots of Eurycoma longifolia Jack, exhibits cytotoxic effect on cancer cells. It activates the mTOR signaling pathway, reduces autophagy level, and inhibits colorectal cancer tumorigenesis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts

Nathalia D. de Moura Sperotto, Rodrigo Braccini Madeira Silva, Marcia Alberton Perello, Ana Flavia Borsoi, Adilio da Silva Dadda, Candida Deves Roth, Raquel Dal Sasso Freitas, Ana Paula Duarte de Souza, Deise do Nascimento de Freitas, Jaqueline Nascimento Picada, Jayne Torres de Sousa, Debora Dreher Nabinger, Stefani Altenhofen, Carla Denise Bonan, Valnes S. Rodrigues-Junior, Cristiano Valim Bizarro, Luiz Augusto Basso, Pablo Machado

Summary: The study investigated the effects of the hTP inhibitor CPBMF-223 in a xenograft tumor model induced by human colorectal carcinoma cells, showing significant inhibition of tumor growth, reduction in vessel number, and decrease in cell migration. Additionally, CPBMF-223 demonstrated a favorable toxicity profile and pharmacokinetic characteristics, highlighting its potential as a promising drug candidate for colorectal cancer.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Oncology

Treatment of Peritoneal Metastasis with Pressurized Intraperitoneal Aerosol Chemotherapy: Results from the Prospective PIPAC-OPC2 Study

Martin Graversen, S. Detlefsen, A. P. Ainsworth, C. W. Fristrup, A. O. Knudsen, P. Pfeiffer, L. S. Tarpgaard, M. B. Mortensen

Summary: This study evaluated the Peritoneal Regression Grading score (PRGS) and its prognostic value in patients with peritoneal metastasis. The results showed that 61% of patients had a complete or major histological response after three PIPAC treatments, which was the only independent prognostic factor. PIPAC treatment can induce significant histological response and provide important prognostic information for patients.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study

Eran van Veldhuisen, Sjors Klompmaker, Quisette P. Janssen, Mohammed Abu Hilal, Adnan Alseidi, Alberto Balduzzi, Gianpaolo Balzano, Claudio Bassi, Frederik Berrevoet, Morgan Bonds, Olivier R. Busch, Giovanni Butturini, Kevin C. Conlon, Isabella M. Frigerio, Giuseppe K. Fusai, Johan Gagniere, Oonagh Griffin, Thilo Hackert, Asif Halimi, Tobias Keck, Joerg Kleeff, Ulla Klaiber, Knut J. Labori, Mickael Lesurtel, Giuseppe Malleo, Marco V. Marino, I. Quintus Molenaar, Michael B. Mortensen, Andrej Nikov, Michele Pagnanelli, Rupaly Pande, Per Pfeiffer, Daniel Pietrasz, Elena Rangelova, Keith J. Roberts, Antonio Sa Cunha, Roberto Salvia, Oliver Strobel, Timo Tarvainen, Johanna W. Wilmink, Bas Groot Koerkamp, Marc G. Besselink

Summary: This international multicenter retrospective cohort study found that pancreatectomy after preoperative FOLFIRINOX chemotherapy is associated with favorable outcomes for patients with borderline resectable and locally advanced pancreatic cancer. The study also found that R0 resection and tumor differentiation are predictors of overall survival, while the number of preoperative chemotherapy cycles and the use of adjuvant chemotherapy are not associated with overall survival.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

ASO Visual Abstract: Treatment of Peritoneal Metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy-Results from the Prospective PIPAC-OPC2 Study

M. Graversen, S. Detlefsen, A. P. Ainsworth, C. W. Fristrup, A. O. Knudsen, P. Pfeiffer, L. S. Tarpgaard, M. B. Mortensen

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Therapy with pembrolizumab in treatment-naive patients with nonmetastatic, mismatch repair deficient colorectal cancer

Rikke Lovendahl Eefsen, Jim S. S. Larsen, Louise L. L. Klarskov, Rahim Altaf, Estrid Hogdall, Peter Ingeholm, Jakob Lykke, Dorte L. L. Nielsen, Per Pfeiffer, Laurids O. Poulsen, Camilla Qvortrup, Jakob V. V. Schou, Morten Mau-Sorensen, Kell Osterlind, Benny V. V. Jensen

Summary: Therapy with immune checkpoint inhibitors has shown effectiveness in patients with metastatic mismatch-repair deficient colorectal cancer. However, the data on neoadjuvant ICI treatment in locally advanced CRC patients are limited. A study in Danish oncological centers evaluated the use of preoperative pembrolizumab in 10 treatment-naive dMMR CRC patients, demonstrating feasibility and effectiveness.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy-The randomized NORDIC9-study

Gabor Liposits, Jesper Ryg, Halla Skuladottir, Stine B. Winther, Soren Moller, Eva Hofsli, Carl-Henrik Shah, Laurids ostergaard Poulsen, Ake Berglund, Camilla Qvortrup, Pia Osterlund, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Summary: This study explores the prognostic value of four functional status measures in vulnerable older patients with metastatic colorectal cancer (mCRC) receiving first-line palliative chemotherapy. The results show that ECOG performance status, frailty phenotype, G8, and VES-13 are all effective tools for assessing overall survival in these patients.

JOURNAL OF GERIATRIC ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

ASO Visual Abstract: Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence: The PIPAC-OPC4 Study

M. Graversen, I. Rouvelas, A. P. Ainsworth, A. P. Bjarnesen, S. Detlefsen, S. B. Ellebaek, C. W. Fristrup, M. G. Liljefors, L. Lundell, M. Nilsson, P. Pfeiffer, L. S. Tarpgaard, A. Tsekrekos, M. B. Mortensen

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Soenke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl

Summary: This study aims to investigate whether reduced dose GemNab is superior to full dose Gem in patients with resectable pancreatic cancer. The study will explore various endpoints including progression-free survival, overall survival, overall response rate, quality of life, toxicity, and rate of hospitalizations. The correlation between blood inflammatory markers, circulating tumor DNA, tissue biomarkers, and chemotherapy resistance will also be studied, along with measures of frailty to assess personalized treatment allocation or interventions.

BMC CANCER (2023)

Add to Collection

Article Oncology

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Tiuri E. Kroese, Hanneke W. M. van Laarhoven, Sebastian F. Schoppman, Pieter R. A. J. Deseyne, Eric van Cutsem., Karin Haustermans., Philippe. Nafteux, Melissa Thomas, Radka Obermannova, Hanna R. Mortensen, Marianne Nordsmark, Per Pfeiffer, Anneli Elme, Antoine Adenis, Guillaume Piessen, Christiane J. Bruns, Florian Lordick, Ines Gockel, Markus Moehler, Cihan Gani, Theodore Liakakos, John Reynolds, Alessio G. Morganti, Riccardo Rosati, Carlo Castoro, Francesco Cellini, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Jolanda van Dieren, Marieke Vollebergh, Johanna W. van Sandick, Paul Jeene, Christel T. Muijs, Marije Slingerland, Francine E. M. Voncken, Henk Hartgrink, Geert-Jan Creemers, Maurice J. C. van der Sangen, Grard Nieuwenhuijzen, Maaike Berbee, Marcel Verheij, Bas Wijnhoven, Laurens V. Beerepoot, Nadia H. Mohammad, Stella Mook, Jelle P. Ruurda, Piotr Kolodziejczyk, Wojciech P. Polkowski, Lucjan Wyrwicz, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Andres Cervantes, Magnus Nilsson, Stefan Monig, Anna D. Wagner, Matthias Guckenberger, Ewen A. Griffiths, Elizabeth Smyth, George B. Hanna, Sheraz Markar, M. Asif Chaudry, Maria A. Hawkins, Edward Cheong, Richard van Hillegersberg, Peter S. N. van Rossum

Summary: This study aimed to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophago-gastric cancer. Through a series of discussions and expert evaluations, a consensus was reached, which can be used for future research in clinical trials.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Medicine, General & Internal

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol

Tobias Freyberg Justesen, Ismail Gogenur, Line Schmidt Tarpgaard, Per Pfeiffer, Camilla Qvortrup

Summary: In the past two decades, there have been significant advances in the surgical approach for colorectal cancer patients. However, reducing surgery-related complications and improving long-term oncological outcomes still present challenges. Studies have shown promising response rates in immunotherapy for colorectal cancer patients with mismatch repair deficiency (dMMR). This study aims to investigate the effects of neoadjuvant immunotherapy and identify predictive biomarkers.

BMJ OPEN (2023)

Add to Collection

Article Oncology

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

C. J. A. Punt, V. Heinemann, T. Maughan, C. Cremolini, E. Van Cutsem, R. McDermott, G. Bodoky, T. Andre, P. Osterlund, A. J. Teske, P. Pfeiffer

Summary: Fluoropyrimidines are widely used in the treatment of metastatic colorectal cancer. S-1, an oral fluoropyrimidine, has been approved for use as monotherapy or in combination with other drugs. An international group of oncologists formulated recommendations for the use of S-1 based on published data.

ESMO OPEN (2023)

Add to Collection

Article Oncology

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population

N. H. Paulsen, P. Pfeiffer, M. Ewertz, S. Feddersen, H. S. Holm, T. K. Bergmann, C. Qvortrup, P. Damkier

Summary: The study aimed to compare the frequency of grade >3 FP-TOX before and after the implementation of DPYD genotyping. The results showed that the overall frequency of grade >3 FP-TOX was 27% in the DPYD genotype-guided group compared to 24% in the historical cohort. DPYD genotyping reduced the frequency of FP-related hospitalization from 19% to 0% in DPYD variant carriers. In wild-type patients, those with uracil >16 ng/mL had a higher frequency of FP-TOX than those with uracil <16 ng/mL.

ESMO OPEN (2023)

Add to Collection

Article Oncology

Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts

Emerik Osterlund, Ari Ristimaki, Markus J. Makinen, Soili Kytola, Juha Kononen, Per Pfeiffer, Leena-Maija Soveri, Mauri Keinanen, Halfdan Sorbye, Luis Nunes, Tapio Salminen, Lasse Nieminen, Aki Uutela, Paivi Halonen, Annika Algars, Jari Sundstrom, Raija Kallio, Raija Ristamaki, Annamarja Lamminmaki, Hanna Stedt, Eetu Heerva, Teijo Kuopio, Tobias Sjoblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund

Summary: BRAF-V600E mutation is a negative prognostic and predictive biomarker in metastatic colorectal cancer. Non-V600E mutations (aBRAFmt) are rare and poorly understood. This study compared the mutation patterns and characteristics of aBRAFmt with other RAS/BRAF groups in three different cohorts. The study found that aBRAFmt represents a distinct subgroup with differences in clinicopathological features, and its prognosis is slightly better than BRAF-V600E but worse than RASmt and RAS & BRAFwt. aBRAFmt should not be a contraindication for metastasectomy.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. S. Hochster

Summary: This meta-analysis indicates that trifluridine/tipiracil plus bevacizumab is more effective and tolerable than trifluridine/tipiracil for refractory metastatic colorectal cancer. Despite the lack of randomized controlled trial data, the results consistently support the use of the combination therapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials

Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer

Summary: Pancreatic cancer is a leading cause of cancer-related death worldwide, and the management of locally advanced or metastatic disease is difficult due to limited treatment options. While systemic chemotherapy is commonly used, the role of radiotherapy in treatment remains unclear. This review explores the available data on radiotherapy, chemoradiation, and stereotactic body radiation therapy for locally advanced pancreatic cancer. The included studies showed conflicting results and high heterogeneity, highlighting the need for further research to improve outcomes and define the role of radiation therapy in pancreatic cancer.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Oncology

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study

Eran van Veldhuisen, Sjors Klompmaker, Quisette P. Janssen, Mohammed Abu Hilal, Adnan Alseidi, Alberto Balduzzi, Gianpaolo Balzano, Claudio Bassi, Frederik Berrevoet, Morgan Bonds, Olivier R. Busch, Giovanni Butturini, Kevin C. Conlon, Isabella M. Frigerio, Giuseppe K. Fusai, Johan Gagniere, Oonagh Griffin, Thilo Hackert, Asif Halimi, Tobias Keck, Joerg Kleeff, Ulla Klaiber, Knut J. Labori, Mickael Lesurtel, Giuseppe Malleo, Marco V. Marino, I. Quintus Molenaar, Michael B. Mortensen, Andrej Nikov, Michele Pagnanelli, Rupaly Pande, Per Pfeiffer, Daniel Pietrasz, Elena Rangelova, Keith J. Roberts, Antonio Sa Cunha, Roberto Salvia, Oliver Strobel, Timo Tarvainen, Johanna W. Wilmink, Bas Groot Koerkamp, Marc G. Besselink

Summary: This study aimed to evaluate the outcome of pancreatectomy after preoperative FOLFIRINOX chemotherapy, and found that this treatment is associated with favorable outcomes for patients with BRPC and LAPC. However, the number of preoperative chemotherapy cycles and the use of adjuvant chemotherapy are not related to survival rate.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.